 Cohorts of 3-6 patients receive escalating doses of MDX-CTLA4 until the maximum tolerated dose MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase I is closed to accrual as of 4132004. 